Literature DB >> 32705685

Peripheral chemoreflex control of fetal heart rate decelerations overwhelms the baroreflex during brief umbilical cord occlusions in fetal sheep.

Christopher A Lear1, Michi Kasai1,2, Lindsea C Booth3, Paul P Drury1, Joanne O Davidson1, Yoshiki Maeda1,4, Shoichi Magawa1,4, Etsuko Miyagi2, Tomoaki Ikeda4, Jenny A Westgate1, Laura Bennet1, Alistair J Gunn1.   

Abstract

KEY POINTS: The majority of intrapartum decelerations are widely believed to be mediated by the baroreflex secondary to brief umbilical cord occlusions (UCOs) but this remains unproven. We examined the responses to brief-UCOs in fetal sheep and compared these to a phenylephrine-stimulated baroreflex in a separate cohort. A further cohort was instrumented with near-infrared spectroscopy to measure cerebral oxygenation during UCO. The first 3-4 s of the brief-UCOs were consistent with a baroreflex, and associated with a minor fall in fetal heart rate (FHR). Thereafter, the remainder of the FHR decelerations were highly consistent with the peripheral chemoreflex. The baroreflex is not sufficient to produce deep, rapid decelerations characteristic of variable decelerations and it is therefore likely to be a minor contributor to intrapartum decelerations. ABSTRACT: Fetal heart rate (FHR) monitoring is widely used to assess fetal wellbeing during labour, yet the physiology underlying FHR patterns remains incompletely understood. The baroreflex is widely believed to mediate brief intrapartum decelerations, but evidence supporting this theory is lacking. We therefore investigated the physiological changes in near-term fetal sheep during brief repeated umbilical cord occlusions (brief-UCOs, n = 15). We compared this to separate cohorts that underwent a phenylephrine challenge to stimulate the baroreflex (n = 9) or were instrumented with near-infrared spectroscopy and underwent prolonged 15-min complete UCO (prolonged-UCO, n = 9). The first 3-4 s of brief-UCOs were associated with hypertension (P = 0.000), a fall in FHR by 9.7-16.9 bpm (P = 0.002). The FHR/MAP relationship during this time was consistent with that observed during a phenylephrine-induced baroreflex. At 4-5 s, the FHR/MAP relationship began to deviate from the phenylephrine baroreflex curve as FHR fell independently of MAP until its nadir in association with intense peripheral vasoconstriction (P = 0.000). During prolonged-UCO, cerebral oxygenation remained steady until 4 s after the start of prolonged-UCO, and then began to fall (P = 0.000). FHR and cerebral oxygenation then fell in parallel until the FHR nadir. In conclusion, the baroreflex has a minor role in mediating the first 3-4 s of FHR decelerations during complete UCO, but thereafter the peripheral chemoreflex is the dominant mediator. Overall, the baroreflex is neither necessary nor sufficient to produce deep, rapid decelerations characteristic of variable decelerations; it is therefore likely to be a minor contributor to intrapartum decelerations.
© 2020 The Authors. The Journal of Physiology © 2020 The Physiological Society.

Entities:  

Keywords:  arterial baroreflex; chemoreflex; fetal sheep; fetus; heart rate; near-infrared spectroscopy

Mesh:

Year:  2020        PMID: 32705685     DOI: 10.1113/JP279573

Source DB:  PubMed          Journal:  J Physiol        ISSN: 0022-3751            Impact factor:   5.182


  3 in total

1.  Reply to Smolich and Mynard.

Authors:  Christopher A Lear; Laura Bennet; Benjamin A Lear; Jenny A Westgate; Alistair J Gunn
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2021-10-01       Impact factor: 3.210

2.  Acute fetal hypoxic bradycardia: solving the chemoreception puzzle.

Authors:  Kent L Thornburg
Journal:  J Physiol       Date:  2020-08-26       Impact factor: 5.182

3.  Reply to "Bezold-Jarisch reflex in the near-term fetus during labor: a matter of time".

Authors:  Christopher A Lear; Laura Bennet; Benjamin A Lear; Jenny A Westgate; Alistair J Gunn
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2021-05-01       Impact factor: 3.619

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.